logo
  • Home
  • Technologies
    • Live Cell Encapsulation
    • Research & Development
    • Cancer
    • Diabetes
    • Cannabinoids
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
    • International Diabetes Consortium
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls / Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact

Press Releases

Navigation Toggle Navigation
  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Shareholder Calls / Presentations
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • Mar 22, 2022

PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

  • Mar 16, 2022

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

  • Feb 22, 2022

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

  • Feb 14, 2022

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

  • Jan 6, 2022

PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference

  • Jan 4, 2022

PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells

  • Dec 28, 2021

PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study

  • Dec 15, 2021

PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights

  • Dec 8, 2021

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

  • Nov 30, 2021

PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...29
  • Next »

Contact Us

PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, Nevada 89169
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

Latest News

  • PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells July 5, 2022
  • PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value June 15, 2022